Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: A retrospective, multicenter Polish Adult Leukemia Group study
- 21 September 2015
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 90 (10) , 904-909
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III StudyJournal of Clinical Oncology, 2012
- Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2011
- Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML IntergroupBlood, 2003
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood, 2001
- The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patientsLeukemia, 2001
- Prognostic factors in acute myelogenous leukemiaLeukemia, 2001
- Clinical importance of cytogenetics in acute myeloid leukaemiaBest Practice & Research Clinical Haematology, 2001
- Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group studyBlood, 2000
- The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 TrialBlood, 1998